Advances in Brain Tumor Therapy Based on the Magnetic Nanoparticles.
Authors: Xu S, Zhang G, Zhang J, Liu W, Wang Y, Fu X
Brain tumors, including primary gliomas and brain metastases, are one of the deadliest tumors because effective macromolecular antitumor drugs cannot easily penetrate the blood-brain barrier (BBB) and blood-brain tumor barrier (BTB). Magnetic nanoparticles (MNPs) are considered the most suitable nanocarriers for the delivery of brain tumor drugs because of their unique properties compared to other nanoparticles. Numerous preclinical and clinical studies have demonstrated the potential of these nanoparticles in magnetic targeting, nuclear magnetic resonance, magnetic thermal therapy, and ultrasonic hyperthermia. To further develop and optimize MNPs for the diagnosis and treatment of brain tumors, we attempt to outline recent advances in the use of MNPs to deliver drugs, with a particular focus on their efficacy in the delivery of anti-brain tumor drugs based on magnetic targeting and low-intensity focused ultrasound, magnetic resonance imaging for surgical real-time guidance, and magnetothermal and ultrasonic hyperthermia therapy. Furthermore, we summarize recent findings on the clinical application of MNPs and the research limitations that need to be addressed in clinical translation.
Introduction
Purpose
Drug delivery with BBB opening
Study Objective
To review recent advances in the use of magnetic nanoparticles for diagnosis and treatment of brain tumors, with emphasis on magnetic targeting and low-intensity focused ultrasound drug delivery, MRI-guided surgery, magnetothermal and ultrasonic hyperthermia therapies, and clinical translation challenges.
Animal model / Human subject
Not specified in the provided text.
Disease model
Brain tumors (including primary gliomas and brain metastases)
MRI or image guidance method
Magnetic resonance imaging (MRI) real-time guidance
Targeted brain region(s)
Blood-Brain Barrier (Bbb) And Blood-Brain Tumor Barrier (Btb)
Cargo name and characteristics
Magnetic nanoparticles (MNPs): nanoparticle-based drug carriers (magnetic, e.g., iron-oxide style MNPs) used for delivery of anti–brain tumor agents. Characterized by magnetic targeting capability, utility as MRI contrast agents (nuclear magnetic resonance), and use in magnetothermal and ultrasonic hyperthermia therapies to enhance BBB/BTB penetration and enable image-guided delivery.
Route of administration
Not specified
Outcomes and Safety
Summary of Outcomes
Magnetic nanoparticles improve penetration of the blood–brain and blood–brain tumor barriers to enable noninvasive targeted delivery, MRI-guided imaging, and magnetothermal/ultrasound hyperthermia therapy of brain tumors, although clinical translation is limited by issues of aggregation, clearance, and lack of precise tumor-specific targeting.
Duration of biological effect
past few decades
Safety-related matter
The authors cite safety concerns for clinical translation, including off-target side effects from inadequate tumor specificity that can damage normal CNS tissue, risks from MNP aggregation/precipitation, and issues with metabolic clearance and RES removal that may affect safety and persistence of nanoparticles.
Brain Region
Ultrasound Parameters
Ultrasound instrument
Not reported in provided text.
FUS Frequency
Not reported
FUS Intensity
Not reported
FUS Pressure
Not reported
FUS Mode
pulsed
Pulse duration
Not reported
Duration of a single FUS session
Not stated in the provided text
Focal Characteristics
Not specified
Treatment frequency
not specified
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search